Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study

businesswire

Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study – NEWSnet – News… as it used to be

More Press Releases

May 29, 2026

ANGI Investors Have Opportunity to Join Angi Inc. Fraud Investigation with the Schall Law Firm

May 29, 2026

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

May 29, 2026

CALX Investors Have Opportunity to Lead Calix, Inc. Securities Fraud Lawsuit

May 29, 2026

Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study

ANGI Investors Have Opportunity to Join Angi Inc. Fraud Investigation with the Schall Law Firm

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

CALX Investors Have Opportunity to Lead Calix, Inc. Securities Fraud Lawsuit

Cannabix Expands BreathLogix Alcohol Screening Technology into Mining, Municipal and Aviation Sectors in Australia